358 patents
Page 13 of 18
Utility
Compositions and Their Uses Directed to Huntingtin
21 Jan 21
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
Filed: 10 Aug 20
Utility
Modulation of HSD17B13 Expression
6 Jan 21
Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual.
Susan F. Murray, Jiangwei Zhang, Huynh-Hoa Bui
Filed: 20 Mar 19
Utility
Selective Antisense Compounds and Uses Thereof
6 Jan 21
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 17 Feb 20
Utility
Methods and Compositions for Modulating Apolipoprotein (A) Expression
6 Jan 21
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a).
Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
Filed: 2 Aug 20
Utility
Methods for Modulating FMR1 Expression
6 Jan 21
Provided are methods for increasing the amount or activity of FMR1 RNA, and in certain instances of increasing the amount of FMRP protein, in an animal Such methods are useful to prevent or ameliorate at least one symptom of a Fragile X-Spectrum disorder.
Frank RIGO, Peter TODD, Caitlin RODRIGUEZ
Filed: 21 Mar 19
Utility
Compositions and methods for modulating apolipoprotein (a) expression
4 Jan 21
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 6 Feb 18
Utility
Methods of Modulating Antisense Activity
30 Dec 20
Disclosed herein are methods for increasing antisense activity by modulating EGFR.
Shiyu Wang, Alexey Revenko, Xue-hai Liang, Stanley T. Crooke
Filed: 12 Feb 19
Utility
Compositions and methods for modulating angiopoietin-like 3 expression
28 Dec 20
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
Filed: 25 Feb 18
Utility
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
16 Dec 20
The present invention provides oligomeric compounds.
Susan M. Freier, Eric E. Swayze
Filed: 20 Jan 20
Utility
Compounds and Methods for Reducing Snca Expression
16 Dec 20
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal.
Holly Kordasiewicz, Priyam Singh, Susan M. Freier, Tracy A. Cole
Filed: 8 Nov 18
Utility
Conjugated Antisense Compounds and Their Use
16 Dec 20
The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound.
Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
Filed: 13 Dec 18
Utility
Modulators of DNM2 Expression
16 Dec 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Susan M. FREIER, Huynh-Hoa BUI, Susan F. MURRAY, Brett P. MONIA, Shuling GUO
Filed: 14 Jan 19
Utility
Oligomeric compounds comprising α-β-constrained nucleic acid
14 Dec 20
The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein.
Michael Oestergaard, Eric E. Swayze, Punit P. Seth
Filed: 3 Jan 19
Utility
Modulators of DNM2 expression
14 Dec 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Susan M. Freier
Filed: 14 Jan 19
Utility
5' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
9 Dec 20
The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 29 Apr 20
Utility
Methods for treating hypercholesterolemia
7 Dec 20
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C.
Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
Filed: 6 Aug 18
Utility
Selective Reduction of Allelic Variants
2 Dec 20
Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP).
C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
Filed: 13 Jan 20
Utility
Modulation of SMN expression
30 Nov 20
Certain embodiments are directed to methods and compounds for inhibiting SMN-NAT, the natural antisense transcript of SMN.
Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
Filed: 10 Apr 16
Utility
Conjugated antisense compounds and their use
23 Nov 20
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 25 Dec 18
Utility
Modulating Apolipoprotein (A) Expression
18 Nov 20
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
Filed: 29 Dec 19